recombinant human gdf-5

Recombinant proteinexperimental

Clinical trial activity

5 trials · 13 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
5
Phase 3
0
Phase 4
0

Earliest trial started Jul 1, 2007 (NCT00519155)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Also known as

  • recombinant human gdf-5
  • rhgdf-5

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01182337Phase 1/Phase 2 (Phase 2)Jun 1, 2010DePuy, Janssen Pharmaceutica NV
NCT01158924Phase 1/Phase 2 (Phase 2)Mar 1, 2010DePuy, Johnson and Johnson
NCT01124006Phase 2Jan 1, 2010DePuy
NCT00813813Phase 1/Phase 2 (Phase 2)Jun 1, 2008DePuy, Drug Studies America, Durango Orthopedic Associates/Spine Colorado, Harvard University, Northwestern University, Riverhills Healthcare, Inc., Texas Back Institute, Virginia Commonwealth University
NCT00519155Phase 2Jul 1, 2007FGK Clinical Research GmbH, Radboud University, Scil Technology GmbH
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (13)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
DePuyFor profit4412008
Drug Studies AmericaFor profit1012008
Durango Orthopedic Associates/Spine ColoradoAcademic/Hospital1012008
FGK Clinical Research GmbHFor profit1012007
Harvard UniversityAcademic/Hospital1012008
Janssen Pharmaceutica NVFor profit1012010
Johnson and JohnsonFor profit1012010
Northwestern UniversityAcademic/Hospital1012008
Radboud UniversityAcademic/Hospital1012007
Riverhills Healthcare, Inc.Academic/Hospital1012008
Scil Technology GmbHFor profit1112007
Texas Back InstituteAcademic/Hospital1012008
Virginia Commonwealth UniversityAcademic/Hospital1012008
13 organizations
Page 1 / 1